Bellerophon Therapeutics Statistics
Total Valuation
Bellerophon Therapeutics has a market cap or net worth of 146,792. The enterprise value is -4.24 million.
| Market Cap | 146,792 |
| Enterprise Value | -4.24M |
Important Dates
The next estimated earnings date is Monday, March 31, 2025.
| Earnings Date | Mar 31, 2025 |
| Ex-Dividend Date | Dec 19, 2024 |
Share Statistics
Bellerophon Therapeutics has 12.23 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 12.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 8.20% |
| Owned by Institutions (%) | 8.43% |
| Float | 11.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.02 |
| PB Ratio | 0.04 |
| P/TBV Ratio | 0.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.46 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.96
| Current Ratio | 3.96 |
| Quick Ratio | 3.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -165.96% and return on invested capital (ROIC) is -119.52%.
| Return on Equity (ROE) | -165.96% |
| Return on Assets (ROA) | -78.47% |
| Return on Capital (ROIC) | -119.52% |
| Revenue Per Employee | 313,333 |
| Profits Per Employee | -514,056 |
| Employee Count | 18 |
| Asset Turnover | 0.64 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.57% in the last 52 weeks. The beta is 0.70, so Bellerophon Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -67.57% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 28.27 |
| Average Volume (20 Days) | 35,061 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.17 |
Income Statement
In the last 12 months, Bellerophon Therapeutics had revenue of 5.64 million and -9.25 million in losses. Loss per share was -0.83.
| Revenue | 5.64M |
| Gross Profit | 5.64M |
| Operating Income | -11.04M |
| Pretax Income | -10.53M |
| Net Income | -9.25M |
| EBITDA | -11.04M |
| EBIT | -11.04M |
| Loss Per Share | -0.83 |
Balance Sheet
| Cash & Cash Equivalents | 4.38M |
| Total Debt | n/a |
| Net Cash | 4.38M |
| Net Cash Per Share | 0.36 |
| Equity (Book Value) | 3.72M |
| Book Value Per Share | 0.30 |
| Working Capital | 3.72M |
Cash Flow
| Operating Cash Flow | -12.34M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -195.76% and -164.06%.
| Gross Margin | 100.00% |
| Operating Margin | -195.76% |
| Pretax Margin | -186.70% |
| Profit Margin | -164.06% |
| EBITDA Margin | -195.66% |
| EBIT Margin | -195.76% |
| FCF Margin | n/a |
Dividends & Yields
Bellerophon Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.43% |
| Shareholder Yield | -16.43% |
| Earnings Yield | -6,944.96% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on February 10, 2020. It was a reverse split with a ratio of 0.0666666.
| Last Split Date | Feb 10, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.0666666 |
Scores
Bellerophon Therapeutics has an Altman Z-Score of -63.37. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -63.37 |
| Piotroski F-Score | n/a |